LC-MS/MS Biomarker Analysis Without Derivatization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical diagnostic methods for endogenous biomarkers, such as hormones and thyroid hormones, face challenges with low throughput, antibody cross-reactivity, and the need for cumbersome derivatization processes, especially when analyzing small sample volumes and multiple analytes simultaneously.
Innovation Solution
The use of liquid chromatography (LC) combined with tandem mass spectrometry (MS/MS) techniques, including dehydration of biomarkers like estradiol and dialysis for separating free thyroxine, allows for high-sensitivity and high-throughput analysis of endocrine biomarkers without the need for derivatization, enabling precise measurement of hormones like estrone, estradiol, and thyroid hormones in small sample volumes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radioimmunoassay (RIA) and enzyme-linked immunoassay (ELISA) methods are used for clinical diagnostic testing, then antibody-based detection can be achieved, but throughput is low and multiple serial dilutions are required for each individual marker
Solution Approach 1:
The patent replaces the mechanical/chemical immunoassay system (RIA, ELISA) with a mass spectrometry-based analytical system. LC-MS/MS uses mass-to-charge ratio detection instead of antibody-antigen binding, eliminating the need for multiple serial dilutions and enabling simultaneous analysis of multiple biomarkers in a single run, thus dramatically improving throughput while maintaining detection sensitivity
Solution Approach 2:
The LC-MS/MS system provides universal detection capability for multiple different biomarkers (steroid hormones, thyroid hormones, vitamins, metabolites) using a single analytical platform. This multi-functional approach allows simultaneous quantification of various analytes without requiring separate assays for each marker, resolving the contradiction between detection precision and productivity
2Reliability
If immunoassay methods are used, then antibody cross-reactivity can be detected, but extra preparation is required for specificity and scalability is poor
Solution Approach 1:
The patent substitutes the antibody-based recognition mechanism with mass spectrometry detection. MS/MS provides inherent specificity through precise mass-to-charge ratio measurement and fragmentation pattern analysis, eliminating antibody cross-reactivity issues and the need for extensive validation and preparation work, thus improving reliability while reducing preparation complexity
Solution Approach 2:
The patent changes the detection parameter from antibody binding affinity to mass-to-charge ratio. This parameter change enables direct and specific identification of biomarkers based on their unique mass characteristics, eliminating the need for complex antibody validation and preparation procedures while maintaining high specificity
3Measurement precision
If multiple serial dilutions are performed for each individual marker, then detection sensitivity can be maintained, but multiple separate tests are required and sample volume requirements increase
Solution Approach 1:
The LC-MS/MS system performs universal detection of multiple biomarkers simultaneously in a single analytical run. This multi-functional capability eliminates the need for multiple separate tests and serial dilutions for each individual marker, reducing total sample volume requirements while maintaining detection sensitivity through direct quantification
Solution Approach 2:
The patent merges the analysis of multiple different biomarkers into a single LC-MS/MS assay. By combining detection of steroid hormones, thyroid hormones, vitamins, and metabolites in one run, the system reduces the cumulative sample volume needed compared to performing separate immunoassays for each marker
4Measurement precision
If GC-MS or LC-MS/MS with derivatization is used for small sample volumes, then detection sensitivity can be achieved, but the derivatization process is cumbersome
Solution Approach 1:
The patent replaces the chemical derivatization process with direct LC-MS/MS analysis. By utilizing the inherent ionization capabilities of the mass spectrometer and optimizing the chromatographic separation, the system achieves high detection sensitivity for small sample volumes without requiring additional derivatization chemistry steps, thus simplifying the overall assay procedure
Solution Approach 2:
The patent extracts and eliminates the derivatization step from the analytical workflow. By demonstrating that direct LC-MS/MS analysis can achieve sufficient sensitivity and selectivity without chemical modification of the analytes, the method removes this cumbersome preparation step while maintaining detection capabilities for small sample volumes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides sensitive and efficient quantification of biomarkers at clinically relevant levels, overcoming the limitations of existing methods by enabling analysis of multiple analytes in a single assay with improved scalability and reduced sample volume requirements.
Implementation Method 1
chromatographically separating the at least one biomarker of interest from other components in the sample
Implementation Method 2
analyzing the chromatographically separated at least one biomarker of interest by mass spectrometry to determine the presence or amount of the at least one biomarker of interest in the sample
Implementation Method 3
dehydration of biomarkers like estradiol
Implementation Method 4
dialysis for separating free thyroxine
Data Source
AI summary
Disclosed are methods and systems using liquid chromatography/tandem mass spectrometry (LC-MS/MS and 2D-LC-MS/MS) for the analysis of endogenous biomarkers, including steroid hormones, such as estrone and estradiol, thyroid hormones, such as free thyroxine, and metabolites, such as 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, in biological samples.